MicroGenesys' VaxSyn HIV-1
Wyeth-Ayerst plans to terminate its relationship with Meriden, Conn.-based firm for the development of the company's gp 160 AIDS therapeutic vaccine, Wyeth-Ayerst reports Jan. 14. Commenting on the end of an R&D collaboration that has existed since 1990, Wyeth-Ayerst research president Robert Levy, MD, said: "We have agreed to unwind our involvement with this project on amicable terms." A Phase III trial of VaxSyn HIV-1 that was scheduled to utilize a $20 mil. congressional appropriation to DoD was postponed for review by FDA and NIH until April 1994. MicroGeneSys had hoped to have patients receiving vaccine by early 1994...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth